Search - tctmd.com

Displaying 141 - 160 of 334

Sort: Relevancy | Date

FDA Approves Empagliflozin for Treatment of HFpEF

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

As COVID-19 Vaccine Boosters Roll Out to Younger Kids, Will Myocarditis Cases Rise?

News Features

As COVID-19 Vaccine Boosters Roll Out to Younger Kids, Will Myocarditis Cases Rise?

January 13, 2022

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

December 07, 2021

Canagliflozin Improves Quality of Life in HF Patients

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

News Conference News AHA 2021

No Benefit for Icosapent Ethyl, P2Y12 Inhibitors in Separate COVID-19 Trials

November 15, 2021

Stimulants Linked to Early Risk of CV Events in Elderly

News Daily News

Stimulants Linked to Early Risk of CV Events in Elderly

Michael O'Riordan

October 25, 2021

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

News Daily News

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

October 20, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

Diabetes Progression in Statin-Treated Patients: VA Data

News Daily News

Diabetes Progression in Statin-Treated Patients: VA Data

Michael O'Riordan

October 06, 2021

Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF

News Conference News HFSA 2021

Digital App Improves HF Quality-of-Care Metrics: CONNECT-AF

Michael O'Riordan

September 14, 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

September 13, 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

News Conference News ESC 2021

IAMI: Influenza Vaccine Beneficial for Post-MI Patients

Michael O'Riordan

August 30, 2021

Uptick in ‘Implausible’ Cancers Reported After ARB Recalls

News Daily News

Uptick in ‘Implausible’ Cancers Reported After ARB Recalls

August 20, 2021

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

News Daily News

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

August 04, 2021

ARBs Preferable to ACE Inhibitors in Large Observational Hypertension Study

News Daily News

ARBs Preferable to ACE Inhibitors in Large Observational Hypertension Study

Michael O'Riordan

July 27, 2021

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

News Daily News

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Yael L. Maxwell

July 09, 2021

Making the Case for Sex-Specific CVD Guidelines

News Daily News

Making the Case for Sex-Specific CVD Guidelines

July 08, 2021

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

July 06, 2021

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

News Daily News

Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b

June 22, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.